Comparison of Weight Loss Diabetic Medication and Self-reported Obesity Prevalence Rates in the United States in 2021
| dc.creator | Neilsen Gazo, Bryce Fukunaga | |
| dc.date.accessioned | 2024-11-23T00:33:38Z | |
| dc.date.available | 2024-11-23T00:33:38Z | |
| dc.date.issued | 2024-11-22 | |
| dc.description.abstract | Poster Title: Comparison of weight loss diabetic medication prescribing and self-reported obesity prevalence rates in the United States in 2021 Authors: Neilsen Gazo, P3 Student Pharmacist; Bryce Fukunaga, PharmD Purpose - According to the ADA 2023 guidelines, glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are effective medications for weight loss in individuals with diabetes. Given the substantial health risks, a focus on weight management is vital. The purpose of this study is to determine if there is an association between the prescribing rates of weight loss diabetic medications, GLP1RA and SGLT2i, and obesity prevalence rates in the United States. Methods - This was a retrospective data analysis, utilizing state prescription information from the 2021 Medicare Provider Utilization and Payment: Part D Prescriber Data. Data on claims and beneficiaries of weight loss diabetic medications across all 50 states available in 2021 were collected, including GLP1RA (Dulaglutide, Exenatide, Liraglutide, Lixisenatide, and Semaglutide) and SGLT2i (Canagliflozin, Dapagliflozin, Empagliflozin, and Ertugliflozin). Prescribing rates for GLP1RA and SGLT2i, both individually and together, were analyzed. Combination medications containing these agents were excluded. Information on the prevalence of self-reported obesity among adults in the United States for 2021 was gathered from the Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance System (CDC BRFSS). Graphs and heat maps were generated using Microsoft Excel for visual representations. Results - In 2021, the top five states with the highest GLP1RA prescribing rates were Alaska, North Dakota, Massachusetts, North Carolina, and New York. The top five states with the highest SGLT2i prescribing rates were Hawaii, New York, Pennsylvania, Connecticut, and Kentucky. The top five states with the highest GLP1RA plus SGLT2i prescribing rates were New York, Alaska, Hawaii, Pennsylvania, and North Carolina. The top ten states with the highest self-reported obesity prevalence rates were West Virginia, Kentucky, Alabama, Oklahoma, Mississippi, Arkansas, Louisiana, South Dakota, Ohio, and Missouri. Kentucky had one of the highest SGLT2i prescribing rates and was also within the top ten states with the highest self-reported obesity prevalence rates. All other states mentioned in the top five states for GLP1RA, SGLT2i, and GLP1RA plus SGLT2i prescribing rates were not among the top ten states with the highest self-reported obesity prevalence rates. Conclusion - There was no strong correlation between the prescribing rates of GLP1RA and SGLT2i and obesity prevalence rates in the United States in 2021. Some limitations of this study include limited age group populations of Medicare Part D data and the subjectiveness of self-reported obesity prevalence. Further research is warranted to observe larger sample sizes with greater ranges of age groups to further evaluate the correlation of this study | |
| dc.format | Image | |
| dc.identifier.uri | https://hdl.handle.net/10790/43900 | |
| dc.language | eng | |
| dc.rights | http://rightsstatements.org/vocab/InC-EDU/1.0/ | |
| dc.title | Comparison of Weight Loss Diabetic Medication and Self-reported Obesity Prevalence Rates in the United States in 2021 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Comparison of Weight Loss Diabetic Medication.pdf
- Size:
- 329.65 KB
- Format:
- Adobe Portable Document Format
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.73 KB
- Format:
- Item-specific license agreed upon to submission
- Description: